

### 6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020 sciforum.net/conference/ECMC2020

### Selection of RNA aptamers targeting the 3' untranslated region of the West Nile Virus genome

#### Ana Hinckley Boned, Cristina Romero-López, and Alfredo Berzal-Herranz\*

<sup>1</sup> Instituto de Parasitología y Biomedicina "López-Neyra", IPBLN-CSIC PTS Granada. Av del Conocimiento 17, 18016 Granada, Spain.

\* Corresponding author: aberzalh@ipb.csic.es



sponsored by

### Selection of RNA aptamers targeting the 3' untranslated region of the West Nile Virus genome



pharmaceuticals

MDPI

sponsored:

6th International Electronic Conference on **Medicinal Chemistry** 



1-30 November 2020

**Abstract:** West Nile Virus (WNV) is a positive polarity, single-stranded RNA virus that causes West Nile fever, for which no cure has been found to date. WNV, like other RNA viruses, needs to compact all the information to complete the viral cycle into a very small genome. Beyond the information that is stored in the primary structure, the genome of RNA viruses bear functional structural domains that perform multiple essential functions for the viral cycle. In WNV, several of these functional domains are found in the 3'UTR region. Based on the importance of these functional domains, in this work, RNA aptamers have been studied as a possible therapeutic agent. Aptamers are oligonucleotides with the ability to efficiently bind to a molecule, not taking into account only the sequence of the target but also its structural motifs. In this work, various aptamers directed against the 3'UTR region of WNV, which could potentially inhibit processes of the WNV viral cycle, have been analysed and selected by *in silico* analysis. We have also studied certain characteristics of the SL-I structural element of the WNV 3'UTR, which shows a high chance of interacting with host molecules. This work will lead further studies towards the generation of antiviral aptamers against WNV and a deeper understanding of WNV interaction with the host cell.

**Keywords:** aptamer, functional RNA domains, RNA genome, RNA structure, RNA-RNA interactions, West Nile Virus.

pharmaceuticals

sponsored: MDPI



### **Introduction- WNV**





6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

### **Introduction- Genome organization of WNV**





6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

### Introduction- Functional structural RNA elements of WNV genome

 $WNV \rightarrow Small genome$ **Complex viral cycle** Need for coordination between replication and translation SLA SLB **Necessary compaction of** information in elements superimposed on the sequence 5'UTR WNV Structural elements with fundamental functions for viral cycle regulation



Schematic representation of the secondary structure of the 5' and 3' UTRs of the WNV RNA genome. The main structural motifs and proposed functions are depicted.



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored:

### **Introduction- Selection of Aptamers**



They recognize both the primary structure and the three-dimensional conformation of the target

Unbound RNA Incubation and selection **RNA** Library (only 1st round) **Bound RNA** SELEX **Elution** and amplification Molecular target Repeat selection using enriched aptamers (Multiple rounds)

Schematic representation of the standard procedure for the selection of aptamers (SELEX). It consists of iterative cycles of binding, selection and amplification



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI



### Introduction- Aptamers against WNV genomic 3'UTR

6th International Electronic Conference on

Medicinal Chemistry 1-30 November 2020 sponsored: MDP

#### **Results- Aptamers are structurally selected in for clusters**



Table summarizes the number of aptamers classified in each cluster. Those representatives showing more than one theoretical structure prediction were excluded of the analysis.

pharmaceuticals

sponsored: MDPI



# Results- Increase in the interaction affinity leads towards structurally complex aptamers



Decrease of excluded aptamers P6: 11/36 → P9: 9/44

Number of non excluded aptamers in round 6 and ( $\rightarrow$ ) 9 for each cluster

Fixation of secondary structures with the increase of affinity → higher structural complexity = higher affinity



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI







sponsored:

## Results- In silico strategies based on sequence homology predict 10 different targets



## Results- RNAcofold predicts five different targets considering secondary structure



### Results- The aptamer population presents a selection towards the interaction through apical and internal loops



Cluster 1, which interacts mostly through sequences at the tail of the structure, is reduced from round 6 to 9; while cluster 2, which interacts through the loops, increases significantly

> Selection towards more interactive clusters

6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

#### **Results- SL-I(IIB) target dominance and round 9 target diversity**





6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

# Results- There is an increase in sequence conservation from round 6 to 9



sponsored: MDPI

pharmaceuticals

	P6	Р9	P9 without repseq*
Hexanucleotides repeated 6 times or more in the aptamer population	10	29	15
Most repeated hexanucleotide	ACACUA (18 repeats)	CACUAA (16 repeats)	CACUAA (15 repeats)

\*In round 9 there is one whole aptamer sequence repeated 5 times and 3 whole aptamer sequences repeated twice.



### Results- Sequences are conserved because of their interaction with WNV 3'UTR



Visual analysis of the location of hexanucleotide motifs within the aptamer





3'WNV interaction



Most repeated hexanucleotides and their hexanucleotide motif location. Between brackets, the amount of hexanucleotides from the total of repeats that are part of the sequence that interacts with WNV 3'UTR.

The conserved sequences interact, at least in part, with WNV 3'UTR



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI pharmaceuticals

## Results- The putative target of the conserved sequences is preferently SL-I(IIB)

N	Clusta Aultiple alig	al Omega nment software	Analysis of the putative targets in WNV 3'UTR of the conserved hexanucleotide sequences	A aptar	Analysis of the number of ners in each round that don't have any conserved hexanucleotide	
	Round	٦	<b>Farget interactions</b>	arget interactions		
	6	SL-I(IIB)	(7/7), CS2 (2), SL-I (LA) (1)	7		
	9	SL-I(IIB) (5/6),	CS2(2), SL-I (LA) (2), no targe	t (1)	13	
		Supp a g ap	oorts the hypothesis of general evolution of tamers towards SL-I	Su b	pports the hypothesis of target diversification etween rounds 6 and 9	

pharmaceuticals

sponsored: MDPI



# Results- The putative target of the conserved sequences is preferently SL-I(IIB)

Search for longer conserved sequences and their putative targets through analysis of the adjoining nucleotides of the conserved hexanucleotides Clustal Omega

Repeat	Round 6	Round 9	Target
CACUAACACC	6 repeats	2 repeats	SL-I
UUACACUA	7 repeats	0 repeats	SL-I
CACUACAC	3 repeats	5 repeats	SL-I
ACUACACUCG	1 repeats	4 repeats	SL-I

Through this process a new target was found: TL-1

Supports the hypothesis of a general evolution of aptamers towards SL-I

*pharmaceuticals* 



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

#### **Results- Most represented targets present high U% and low C%**

	Sequence	%GC	Α	С	G	U	Sequence	%GC	Α	С	G	U
Compseq	3'UTR	28,57	29,1	23,3	28,3	19,4	Apt P9 (re)	52,36	28	37,1	15,3	19,6
	Apt P6	46,59	30,9	34,4	12,2	22,5	Apt P9	51,48	27,4	39,7	12,3	20,6
%nts	Apt P6(-E)	45,96	32	34,8	11,1	22,1	Apt P9 (-E)	52,22	27,3	39,9	12,3	20,5
	SL-I (IIB)	28,57	23,8	0	28,6	47,6	SL-III	51,61	27,4	27,4	24,2	21
	SL-I (LA)	46,15	30,8	15,4	30,8	23,1	SL-IV	58,82	19,6	27,4	31,4	21,6
Infoseq	SL-I (LI)	11,1	22,2	0	11,1	67	TL1	35,71	28,6	7,1	28,6	35,7
	SL-I (total)	25,97	35,8	3,7	21	39,5	RCS2	56,52	30,4	17,4	39,1	13,1
%GC	InDI-II	31,25	43,8	0	31,2	25	TL2	45,45	27,3	9,1	36,3	27,3
	SL-II (LA)	46,67	33,3	6,7	40	20	sHP	56,25	25	18,7	37,5	18,7
	RCS3	73,33	18,7	25	43,7	12,5	3'SL	58,97	24,3	29,5	29,5	16,7

Most interesting data presented in bold letters.

The targets with higher number of predictions present high U% and low C%, which concordates with the percentages in the aptamers if we consider the G-U pairs

sponsored: MDPI



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

# Results- Higher GC content in the sequences that interact with SL-I compared to the adjoining nucleotides

0	6C pairs make struct their triple hydroge	ures more stable be en bond and their st	cause of A	nalysis of the GC cor interact with WNN	ntent in the sequences that / 3'UTR putative targets
	Comparison o aptamer interac with the %GC of	f the %GC of the ting (int) sequenc the whole aptame	Comparison of the %GC of the target site with the %GC of the 10 adjoining nucleotides (a.n.)		
	Software	Target	Media % int	Media % a.n.	Higher %GC in int
	RNAcofold	SL-I	38,35	19,77	63/67
	RNAcofold	Other targets	47	47,24	2/5
	RNAcofold	Aptamers	34,79	49,03	-
	Clustal Omega	SL-I	36,56	28,43	13/16

40,42

35,18



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

**Clustal Omega** 

**Clustal Omega** 

Other targets

**Aptamers** 

sponsored: MDPI

55,5

49,03

0/10

## Results- G residues make SL-I domain the preferred target site for the selected aptamers





6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

### **Results- G-U pairs are highly present in the interactions** between aptamers and WNV 3'UTR

After observing several G-U pairs in the SL-I structure, we analysed the G-U pairs formed in the interactions between aptamers and WNV 3'UTR



**High frequency of G-U pairs** in interactions, especially for those aptamers derived from round 9

sponsored: MDPI

pharmaceuticals



6th International Electronic Conference on

### Results- G-U pair directionality facilitates target-aptamer interaction



G nucleotide location from the G-U pair in aptamer or in WNV 3'UTR

The selection of a specific directionality of the G-U pair and consequent minor groove size variation seems to be facilitating target-aptamer interaction



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

# Results- Criteria for the selection of aptamers for biochemical analysis

Selection criteria for the aptamers that would be further studied *in vitro*:

1-To obtain a group of aptamers that together, have the maximum number of WNV 3'UTR targets with biological interest predicted.

2-If there are several predictions for the same target, select those aptamers, which yields interactions with lower  $\Delta G$  and / or greater number of interacting nucleotides.

3-If the data were similar between rounds, aptamers from round 9 were selected because of their theoretical higher affinity.

4- Conserved hexanucleotides have SL-I and CS2 as targets. Search for aptamers lacking these hexanucleotide sequence motifs.



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

### **Results- Selected aptamers for biochemical analysis**

Round	Group	Apt	Apt struct	ΔG	Rep hexant	3'WNV putative targets
	1	17	Tail	-17,87	2	[SL-I (LA,IIB)(10)]
6	1	8	Tail	-	0	<b>CS3 (8)</b> [SL-I (IIB)(12)]
	2	57	Apical loop	-19,05	7	[SL-I (IIB)(15)]
9	2	35	Stem, AL	-13,37	0	[RCS2(15)]
	2	23	Apical loop	-	2	TL2-CS2 (8) [SL-I (LA, IIB)(11)]
	2	13	Apical loop	-9,8	0	[InDI-II (14)]
	3	8[5]	Apical loop	-	0	SL-II(LA) (6)
	4	11	IL, AL, Stem	-	2	<b>CS2 (9)</b> [SL-I (IIB)(14)]
	4	24	Internal loop	-	0	<b>SL-III (6)</b> [SL-I (LA, IIB)(11)]
	Ex	9	Stem-AL	-	3	<b>TL-1 (11)</b> [SL-1 (IIB)(12)]

Apt struct, structure of the aptamer that interacts with WNV 3'UTR; rep hexant, number of most repeated hexanucleotides in each aptamer. [] Structures predicted by RNAcofold, () number of nucleotides that interact.

sponsored:

MDP

pharmaceuticals



## Results- The selected aptamers cover most of the biologically interesting structural motifs of WNV 3'UTR



The selected aptamers interact with most of the biologically interesting structural motifs of WNV 3'UTR and may permit the generation of antiviral agents. They also have potential as molecular tools for studying the functions of different structural motifs for a deeper understanding of *Flavivirus* replication and infectious cycles

pharmaceuticals

MDPI

sponsored:



### Conclusions

-The aptamer population shows an evolution throughout the SELEX process, both at the structural complexity level and at the chosen target. Thus, the application of restrictive conditions has promoted the isolation of aptamers against structural elements of the WNV 3'UTR distinct from the SL-I domain.

-The structural element SL-I presents some structural characteristics that make it a highly disposable domain to interact. This supports the interest of a further study of such structural features and their contribution to the completion of the viral cycle.

- 10 aptamers, which theoretically recognize 9 of the biologically relevant structural elements in WNV 3'UTR, have been selected for biochemical analysis.

*-In silico* analysis of the RNA structure and interaction has provided useful information that would reduce the cost of analysis of the whole aptamer population *in vitro* and also given interesting data about structural preferences for RNA-RNA interactions.



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

#### Acknowledgments





#### **European Union**

European Regional Development Fund "A way to build Europe"

This work has been funded by the Spanish *Agencia Estatal de Investigación*: PID2019-104018RB-100/ AEI /10.13039/501100011033



6th International Electronic Conference on Medicinal Chemistry 1-30 November 2020

sponsored: MDPI

